Saltar al contenido
Merck
Todas las fotos(3)

Key Documents

View All Documentation

H2910

Sigma-Aldrich

Hydrochlorothiazide

meets USP testing specifications

Sinónimos:

6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(3)

About This Item

Fórmula empírica (notación de Hill):
C7H8ClN3O4S2
Número de CAS:
58-93-5
Peso molecular:
297.74
EC Number:
200-403-3
MDL number:
MFCD00051765
UNSPSC Code:
12352125
PubChem Substance ID:
24895542
NACRES:
NA.21

agency

USP/NF
meets USP testing specifications

Quality Level

200

form

solid

application(s)

pharmaceutical (small molecule)

SMILES string

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

InChI key

JZUFKLXOESDKRF-UHFFFAOYSA-N

Gene Information

human ... ALB(213) , CA1(759) , CA2(760) , CA4(762) , SLC12A3(6559)

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Carbonic anhydrase inhibitor

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H351

Hazard Classifications

Carc. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
WXBD2727V
SLBZ7352
SLBR7387V
SLBQ2575V
SLBH6369V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

A Dornhorst et al.
Lancet (London, England), 1(8421), 123-126 (1985-01-19)
14 hypertensive men with type II diabetes sequentially received, in random order, hydrochlorothiazide 50 mg twice a day, propranolol 80 mg twice a day, and both drugs in combination. The 3-week treatment periods were separated by a 1-week washout period.
Johannes A N Dorresteijn et al.
Journal of hypertension, 31(2), 393-403 (2012-12-14)
The objective of this study is to determine the effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension. A randomized, four-way, double-blind, crossover study in 31 adults with previously untreated obesity-related
Franz H Messerli et al.
The American journal of medicine, 124(10), 896-899 (2011-10-04)
Hydrochlorothiazide (HCTZ) has become by far the most commonly prescribed antihypertensive drug in the US. In 2008, 47.8 million prescriptions were written for HCTZ alone and 87.1 million prescriptions for HCTZ combinations. However, there is no evidence that HCTZ in
Irfan A Dhalla et al.
Annals of internal medicine, 158(6), 447-455 (2013-04-05)
Some evidence suggests that chlorthalidone may be superior to hydrochlorothiazide for the treatment of hypertension. To compare the effectiveness and safety of chlorthalidone and hydrochlorothiazide in older adults. Propensity score-matched observational cohort study with up to 5 years of follow-up.
George C Roush et al.
Hypertension (Dallas, Tex. : 1979), 59(6), 1110-1117 (2012-04-25)
Hydrochlorothiazide (HCTZ) is widely used for hypertension, and prescriptions for HCTZ outnumber those for chlorthalidone (CTDN) by >20-fold in 2 recent surveys. Some have recently expressed a preference for CTDN. However, head-to-head trials testing the effect of the 2 drugs
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico